| 1 Jemal A,Siegel R,Ward E,et al.Cancer statistics[J].CA Cancer J Clin, 2008,58:71-96.
2 Bristow RE.Predicting surgical outcome for advanced ovarian cancer,surgical standards of care,and the concept of kaizenGynecol[J].Oncol,2009, 112(1):l-3.
3 Dedrick RL,Myers CE,Bungay PM,et aL Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer[J].Cancer Treat Rep,1978;62(1):1-11.
4 Fuiwara K,Armstrong D,Morgan M,et al.Principles and practice of intraperitoneal chemotherapy for ovarian cancer[J].Int J Gynecol Cancer,2007,17:1- 20.
5 Howell SB,Pfeifle CL,Wung WE,et al.Intraperitoneal cisplatin with systemic thiosulfate protection[J].Ann Intern Med,1982,97(6):845-851.
6 Casper ES,Kelsen DP,Alcock NW,et aL IP cisplatin in patients with malignant ascites:pharmacokinetic evaluation and comparison with the iv route[J],Cancer Treat Rep,1983,67(3):235-238.
7 Markman M,Rowinsky E,Hakes T,et aL Phase I trial of intraperitoneal Taxol: A Gynecologic Oncology Group study[J].J Clin Oncol,1992,10:1485-91.
8 Alhayki M,Hopkins L,Le T.Intraperitoneal chemotherapy for epithelial ovarian cancer[J].Obstet Gynecol Surv,2006,61:529-534.
9 Markman M,Walker JI.Intraperitoneal Chemotherapy of Ovarian Cancer:A Review, With a Focus on Practical Aspects of Treatment[J],J Clin Oncol,2006, 24:988.
10 Walker JL,Armstrong DK,Huang HQ,et al.Intraperitoneal catheter outcomes in a phase 3 trial of intravenous vs.intraperitoneal chemotherapy in optimal stageⅢovarian ami primary peritoneal cancer;a Gynecologic Oncology Group study [J].Gynecol Oncol,2006,100:27-32.
11 Markman M,Reichman B,Hakes T,et al.Responses to second-line cisplatinbased intraperitoneal therapy in ovarian cancer;influence of a prior response to intravenous cisplatin[J].J Clin Oncol,1991,9(10):1801-05.
12 Markman M,Brady MF,Spirtos NM,et aL PhaseⅡtrial of intraperitoneal paclitaxel in carcinoma of the ovary,tube,and peritoneum:A Gynecologic Oncology Group study[J].J Clin Oncol,1998,16:2620-24.
13 Ozols RF,Bundy BN,Greer BE,et al;PhaseⅢtrial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stageⅢovarian cancer;A Gynecologic Oncology Group study[J].J Clin Oncol, 2003,21:3194-3200.
14 Fujiwara K,Markman M,Morgan M,et al.Intraperitoneal carboplatui-based chemotherapy for epithelial ovarian cancer[J].Gynecol Oncol,2005,97:10- 15.
15 Howell SB.Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer[J].Int J Gynecol Cancer,2008,18(Suppl)1:20-25.
16 Alberts DS,Liu PY,Hannigan EV,et al.Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stageⅢovarian cancer[J].N Engl J Med,1996,335(26):1950- 55. 1
7 McGuire WP,Hoskins WJ,Brady MF.et al.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stageⅢand stageⅣovarian cancer[J].N Engl J Med,1996,334(1):1-6.
18 Markman M,Bundy BN,Alberts DS,et al PhaseⅢtrial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stageⅢovarian carcinoma:an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group,and Eastern Cooperative Oncology Group[J].J Clin Oncol,2001,19(4):1001-07.
19 Armstrong DK,Bundy B,Wenzel L,et al.Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J].N Engl J Med,2006,354(1):34-43.
20 NCCN Clinical Practice Guidelines in Oncology;Ovarian Cancer.V.1.2008, OV-3. |
